

# **SUPPLEMENTAL MATERIAL**

**Table S1. Procedural data**

|                          | <b>Number of patients, n = 100</b> |
|--------------------------|------------------------------------|
| Second Valve             | 4                                  |
| Pre-dilatation           | 96                                 |
| THV type                 |                                    |
| Self-expanding valve     | 91                                 |
| Balloon expandable valve | 9                                  |
| Device                   |                                    |
| Early-generation device  | 65                                 |
| New-generation device    | 35                                 |
| Post-dilatation          | 63                                 |
| Death                    | 0                                  |
| Myocardial infarction    | 0                                  |
| Aortic dissection        | 2                                  |
| Conversion to SAVR       | 0                                  |
| Annular rupture          | 0                                  |
| Coronary obstruction     | 0                                  |

SAVR, surgical aortic valve replacement; THV, transcatheter heart valve

**Table S2. Conduction disturbance detected by smartwatch leading to therapy**

| Patient # | Age (yrs) | Sex    | Cardiovascular symptoms | Conduction Abnormalities  | Detected by watch | Readmission | Therapy                            |
|-----------|-----------|--------|-------------------------|---|-------------------|-------------|------------------------------------|
| 1         | 67        | Male   | cardiogenic syncope     | af, LBBB, sinus arrest for 8.46 seconds                           | Yes               | Yes         | pacemaker                          |
| 2         | 82        | Male   | palpitations            | frequent ventricular premature                                    | Yes               | No          | beta-block                         |
| 3         | 84        | Male   | no symptoms             | third-degree atrioventricular block, sinus arrest for 4.6 seconds | Yes               | Yes         | pacemaker                          |
| 4         | 72        | Female | palpitations            | frequent ventricular premature                                    | Yes               | No          | potassium chloride for hypokalemia |
| 5         | 87        | Male   | dizziness, nausea       | frequent ventricular premature                                    | Yes               | Yes         | beta-block                         |
| 6         | 63        | Female | no symptoms             | high-degree atrioventricular block                                | Yes               | Yes         | pacemaker                          |
| 7         | 70        | Female | dizziness               | af, LBBB, prolonged RR interval                                   | Yes               | Yes         | pacemaker                          |
| 8         | 81        | Female | dizziness               | af with hypotension   | Yes               | Yes         | amiodarone                         |
| 9         | 67        | Male   | palpitations            | frequent atrial premature with IVCD                               | Yes               | No          | beta-block                         |


af, atrial fibrillation; IVCD, intraventricular conduction disturbance; LBBB, left bundle branch block.

**Table S3. Biometric parameters recorded by watch during 30-day follow-up**

|  | <b>Number of patients, n = 100</b> |
|--|------------------------------------|
| <b>Average weekly hear rate, bpm</b>   |                                    |
| Baseline   | 80.5±10.5                          |
| First week   | 77.6±8.4                           |
| Second week  | 75.9±8.1                           |
| Third week   | 75.1±8.5                           |
| Fourth week  | 75.7±8.0                           |
| <b>Ratio of low oxygen saturation (<math>\geq 90\%</math> and <math>\leq 95\%</math>), %</b> |                                    |
| Baseline   | 10.7±8.7                           |
| First week   | 11.9±4.6                           |
| Second week  | 11.6±4.9                           |
| Third week   | 12.0±5.5                           |
| Fourth week  | 11.7±5.1                           |
| <b>Ratio of abnormal oxygen saturation (<math>&lt; 90\%</math>), %</b>                       |                                    |
| Baseline   | 7.1±13.5                           |
| First week   | 6.5±5.6                            |
| Second week  | 6.3±6.6                            |
| Third week   | 6.4±5.8                            |
| Fourth week  | 6.0±5.7                            |
| <b>Daily steps, steps</b>  |                                    |
| Baseline   | 870±1353                           |
| First week   | 1986±2406                          |
| Second week  | 2707±2716                          |
| Third week   | 3059±3036                          |
| Fourth week  | 3678±3485                          |

Data are presented as mean  $\pm$  SD.

**Figure S1. Biometric parameters recorded by smartwatch at baseline and after discharge**



HR, heart rate.